Peter Ly
Psychiatry · Houston, TXNPI 1386881951
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $11,630 of the $12,946 with a category attached, or 89.8%. It is spread thinly across 34 manufacturers, the largest accounting for just 17.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $3,275 and has fallen 54.5% since, to $1,489 in 2025. Among psychiatry clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 718 payments — averaging $18.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$2K
- AbbVie$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Neos Therapeutics, LP$982
- Supernus Pharmaceuticals, Inc.$736
- Corium, LLC$643
- plus $5K from 28 others
Across 19 payments — averaging $3447.89 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$66K
What the payments were for
- Consulting fees$1,0508%
- Food & beverage$11,63090%
- Education$2652%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ABILIFY MYCITE$1,050
- Vemlidy$111
How this compares
$12,946 in reported general payments places this provider in the 90th percentile of 2,238 psychiatry providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lurasidone Hcl | 54 | $6,137 |
| VyvanseLisdexamfetamine Dimesylate | 16 | $5,732 |
| TrintellixVortioxetine Hydrobromide | 11 | $5,176 |
| Lisdexamfetamine Dimesylate | 11 | $2,572 |
| Duloxetine Hcl | 72 | $1,955 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 37 | $1,478 |
| Vilazodone Hcl | 13 | $1,471 |
| Lamotrigine | 173 | $1,449 |
| Bupropion XlBupropion Hcl | 90 | $1,351 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 18 | $905 |
| Ziprasidone Hcl | 12 | $896 |
| Trazodone Hcl | 141 | $788 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 18 | $570 |
| Propranolol Hcl ErPropranolol Hcl | 18 | $474 |
| Buspirone Hcl | 33 | $465 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse, Trintellix | $344 | $10,90927 claims |
| Almatica Pharma LLCSertraline Hcl | $23 | $33654 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,238 psychiatry providers in Texas.
Other psychiatry in Houston
- Matthew BramsHouston$1.5M
- Frank ChenHouston$941K
- Alice MaoHouston$850K
- Mazhar KhowajaHouston$843K
- Barry GritzHouston$792K
- Aaron PetersonHouston$700K
- Ayesha RashidHouston$641K
- Lawrence GinsbergHouston$502K
- Kathy FlanaganHouston$443K
- Rayan Al JurdiHouston$359K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.